Qualcomm stock is up 13.2% this year, and 42.2% during the past 12 months. Market capitalization has...
Polypore Loses the Charge
11/20/2012 6:00 am EST
The battery component maker's very cautious outlook in this generally oversold market has convinced MoneyShow's Jim Jubak, also of Jubak's Picks, that there may be better buys right now.
Polypore International (PPO) has staged a gradual but solid recovery from its August 28 closing low at $31.39, to reach $37.78 on November 19.
Despite that 20% gain, I still decided to sell the stock out of my Jubak’s Picks portfolio on Friday, November 16. When I sold, I was still looking at a 30.5% loss since I added the stock to my portfolio on January 13.
So why sell? Why not wait until the gradual upward trend reduces my losses even further?
It’s never a good idea to let a desire to “get back to even” drive your investment decisions. In this case, I think the key points in making this decision should be:
- How long it would take Polypore to get back to even or better—in other words, what’s my likely return over what period if I continue to hold?
- How does that compare to the potential returns I could earn from other opportunities in the current market?
I think Polypore’s October 29 report of third-quarter earnings supports a decision to sell. The company earned 37 cents a share, beating the Wall Street consensus by 3 cents a share. However, revenue dropped by 6.6% from the third quarter of 2011, although it came in, at $177.6 million, above the analyst forecast of $174.22 million.
But it’s the company’s guidance that really struck me. I’ve rarely heard such caution from a company that was still optimistic about its long-term potential. The fourth quarter will be better than the third, the company said, but management still adjusted guidance to the low end of the 50 cents to 60 cents range that it had projected earlier. (The analyst consensus for the quarter was 56 cents a share.)
In the company’s very important electric vehicle market, the best the company offered was a belief that certain production facilities anticipated by its customers to start up late in the fourth quarter would indeed start up on schedule.
In other words, Polypore won’t see any improvement in its revenue for separators for batteries in electric vehicles in the fourth quarter, even if the projected factories do go on line. And they might not go into production as anticipated.
Other business lines got equally cautious good news. Health-care customers in Italy resumed production at the end of the third quarter—great, but that’s not the same as projecting actual growth from pre-Euro-debt-crisis trends. In its business of making separators for batteries in the consumer electronics market, the best the company could say was that it expected “no further weakening of the consumer electronics market due to macroeconomic factors.”
Still, without the near correction in the overall market—the S&P 500 stock index is down 8.3% from the September 14 high to the close on November 15—I’d probably be willing to hold on to Polypore with great patience until the electric vehicle and consumer electronics markets recover enough to restore the company to a growth track.
But as I wrote in my recent post, the near correction so far and the volatility yet to come on the Euro debt crisis, uncertainty about growth rates in China, and the US fiscal cliff will, during the remainder of the year, create very attractive buying opportunities in stocks that have the potential to show serious gains in the first half of 2013.
In contrast, I think the potential gains in Polypore are much further down the road. Looking at continuing to own Polypore in terms of opportunity costs, I just think that there will be better places to put the money I realize from this sale to work.
Jubak Global Equity Fund, may or may not now own positions in any stock mentioned in this post. The fund did not own shares of Polypore International as of the end of September. For a full list of the stocks in the fund as of the end of September see the fund’s portfolio here.
Related Articles on STOCKS
Of course, there are arguments as to why China should or should not bow to U.S. demands, and the inv...
Headquartered in New Jersey and founded in 1891, Merck & Co. (MRK) is a global health care compa...
Founded in 1902, Minnesota Mining and Manufacturing (MMM) started as five businessmen set out to min...